We generate high affinity antibodies with exquisite specificity to O-glycoproteins found only on the surface of cancer cells and not healthy tissue. GO’s antibody-based therapies deliver a higher therapeutic window due to their exquisite cancer-specificity, high affinity and fewer off-target effects causing less damage to healthy tissue, and enabling oncologists to increase the efficacy on solid tumors.